Skip to main content
Erschienen in: Clinical and Translational Oncology 1/2014

01.01.2014 | Review article

Treatment of anthracycline extravasations using dexrazoxane

verfasst von: D. Conde-Estévez, J. Mateu-de Antonio

Erschienen in: Clinical and Translational Oncology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Extravasation of cytotoxic agents is a true medical emergency. Dexrazoxane is the only licensed drug for the treatment of anthracycline extravasations. Dexrazoxane proved to be effective and moderately well tolerated. However, alternative approaches for the management of anthracycline extravasations are available such as topical DMSO and cooling. There appears to be general agreement about dexrazoxane usefulness when extravasations involve large volumes of anthracycline and/or central venous access device. Nevertheless, the non-invasive combination of DMSO and cooling is the most commonly described therapy, particularly in small anthracycline extravasations. Further research is still needed to establish unequivocal situations where dexrazoxane must be initiated.
Literatur
1.
Zurück zum Zitat Mullin S, Beckwith MC, Tyler LS. Prevention and Management of Antineoplastic Extravasation Injury. Hosp Pharm. 2000;35:57–74. Mullin S, Beckwith MC, Tyler LS. Prevention and Management of Antineoplastic Extravasation Injury. Hosp Pharm. 2000;35:57–74.
2.
Zurück zum Zitat Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol. 2004;15(6):858–62.PubMedCrossRef Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol. 2004;15(6):858–62.PubMedCrossRef
3.
Zurück zum Zitat Alfaro-Rubio A, Sanmartin O, Requena C, Llombart B, Botella-Estrada R, Nagore E, et al. Extravasation of cytostatic agents: a serious complication of oncological treatment. Actas Dermosifiliogr. 2006;97(3):169–76.PubMedCrossRef Alfaro-Rubio A, Sanmartin O, Requena C, Llombart B, Botella-Estrada R, Nagore E, et al. Extravasation of cytostatic agents: a serious complication of oncological treatment. Actas Dermosifiliogr. 2006;97(3):169–76.PubMedCrossRef
4.
Zurück zum Zitat Watanabe H, Ikesue H, Yoshida M, Yamamoto N, Sakamoto S, Koga T, et al. Protection against the extravasation of anticancer drugs by standardization of the management system. Hosp Pharm. 2008;43(7):571–6.CrossRef Watanabe H, Ikesue H, Yoshida M, Yamamoto N, Sakamoto S, Koga T, et al. Protection against the extravasation of anticancer drugs by standardization of the management system. Hosp Pharm. 2008;43(7):571–6.CrossRef
5.
Zurück zum Zitat Goolsby TV, Lombardo FA. Extravasation of chemotherapeutic agents: prevention and treatment. Semin Oncol. 2006;33(1):139–43.PubMedCrossRef Goolsby TV, Lombardo FA. Extravasation of chemotherapeutic agents: prevention and treatment. Semin Oncol. 2006;33(1):139–43.PubMedCrossRef
6.
Zurück zum Zitat Reeves D. Management of anthracycline extravasation injuries. Ann Pharmacother. 2007;41(7):1238–42.PubMedCrossRef Reeves D. Management of anthracycline extravasation injuries. Ann Pharmacother. 2007;41(7):1238–42.PubMedCrossRef
7.
Zurück zum Zitat Olver IN, Aisner J, Hament A, Buchanan L, Bishop JF, Kaplan RS. A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol. 1988;6(11):1732–5.PubMed Olver IN, Aisner J, Hament A, Buchanan L, Bishop JF, Kaplan RS. A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol. 1988;6(11):1732–5.PubMed
8.
Zurück zum Zitat Bertelli G, Gozza A, Forno GB, Vidili MG, Silvestro S, Venturini M, et al. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol. 1995;13(11):2851–5.PubMed Bertelli G, Gozza A, Forno GB, Vidili MG, Silvestro S, Venturini M, et al. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol. 1995;13(11):2851–5.PubMed
9.
Zurück zum Zitat Creus N, Mateu J, Masso J, Codina C, Ribas J. Toxicity to topical dimethyl sulfoxide (DMSO) when used as an extravasation antidote. Pharm World Sci. 2002;24(5):175–6.PubMedCrossRef Creus N, Mateu J, Masso J, Codina C, Ribas J. Toxicity to topical dimethyl sulfoxide (DMSO) when used as an extravasation antidote. Pharm World Sci. 2002;24(5):175–6.PubMedCrossRef
10.
Zurück zum Zitat Schrijvers DL. Extravasation: a dreaded complication of chemotherapy. Ann Oncol. 2003;14(Suppl 3):iii26–30.PubMed Schrijvers DL. Extravasation: a dreaded complication of chemotherapy. Ann Oncol. 2003;14(Suppl 3):iii26–30.PubMed
11.
Zurück zum Zitat Vano-Galvan S, Jaen P. Images in clinical medicine. Extravasation of epirubicin. N Engl J Med. 2009;360(20):2117.PubMedCrossRef Vano-Galvan S, Jaen P. Images in clinical medicine. Extravasation of epirubicin. N Engl J Med. 2009;360(20):2117.PubMedCrossRef
12.
Zurück zum Zitat Kane RC, McGuinn WD Jr, Dagher R, Justice R, Pazdur R. Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy. Oncologist. 2008;13(4):445–50.PubMedCrossRef Kane RC, McGuinn WD Jr, Dagher R, Justice R, Pazdur R. Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy. Oncologist. 2008;13(4):445–50.PubMedCrossRef
13.
Zurück zum Zitat Hasinoff BB. The use of dexrazoxane for the prevention of anthracycline extravasation injury. Expert Opin Investig Drugs. 2008;17(2):217–23.PubMedCrossRef Hasinoff BB. The use of dexrazoxane for the prevention of anthracycline extravasation injury. Expert Opin Investig Drugs. 2008;17(2):217–23.PubMedCrossRef
14.
Zurück zum Zitat Thougaard AV, Langer SW, Hainau B, Grauslund M, Juhl BR, Jensen PB, et al. A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage. Toxicology. 2010;269(1):67–72. doi:10.1016/j.tox.2010.01.007.PubMedCrossRef Thougaard AV, Langer SW, Hainau B, Grauslund M, Juhl BR, Jensen PB, et al. A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage. Toxicology. 2010;269(1):67–72. doi:10.​1016/​j.​tox.​2010.​01.​007.PubMedCrossRef
15.
Zurück zum Zitat Langer SW, Sehested M, Jensen PB. Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res. 2000;6(9):3680–6.PubMed Langer SW, Sehested M, Jensen PB. Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res. 2000;6(9):3680–6.PubMed
16.
Zurück zum Zitat Langer SW, Sehested M, Jensen PB. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Ann Oncol. 2001;12(3):405–10.PubMedCrossRef Langer SW, Sehested M, Jensen PB. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Ann Oncol. 2001;12(3):405–10.PubMedCrossRef
17.
Zurück zum Zitat Langer SW, Thougaard AV, Sehested M, Jensen PB. Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone. Cancer Chemother Pharmacol. 2006;57(1):125–8.PubMedCrossRef Langer SW, Thougaard AV, Sehested M, Jensen PB. Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone. Cancer Chemother Pharmacol. 2006;57(1):125–8.PubMedCrossRef
18.
Zurück zum Zitat Langer SW, Sehested M, Jensen PB, Buter J, Giaccone G. Dexrazoxane in anthracycline extravasation. J Clin Oncol. 2000;18(16):3064.PubMed Langer SW, Sehested M, Jensen PB, Buter J, Giaccone G. Dexrazoxane in anthracycline extravasation. J Clin Oncol. 2000;18(16):3064.PubMed
19.
Zurück zum Zitat Bos AM, van der Graaf WT, Willemse PH. A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxane. Acta Oncol. 2001;40(4):541–2.PubMedCrossRef Bos AM, van der Graaf WT, Willemse PH. A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxane. Acta Oncol. 2001;40(4):541–2.PubMedCrossRef
20.
Zurück zum Zitat Jensen JN, Lock-Andersen J, Langer SW, Mejer J. Dexrazoxane—a promising antidote in the treatment of accidental extravasation of anthracyclines. Scand J Plast Reconstr Surg Hand Surg. 2003;37(3):174–5.PubMedCrossRef Jensen JN, Lock-Andersen J, Langer SW, Mejer J. Dexrazoxane—a promising antidote in the treatment of accidental extravasation of anthracyclines. Scand J Plast Reconstr Surg Hand Surg. 2003;37(3):174–5.PubMedCrossRef
21.
Zurück zum Zitat El-Saghir N, Otrock Z, Mufarrij A, Abou-Mourad Y, Salem Z, Shamseddine A, et al. Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing. Lancet Oncol. 2004;5(5):320–1.PubMedCrossRef El-Saghir N, Otrock Z, Mufarrij A, Abou-Mourad Y, Salem Z, Shamseddine A, et al. Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing. Lancet Oncol. 2004;5(5):320–1.PubMedCrossRef
22.
Zurück zum Zitat Frost A, Gmehling D, Azemar M, Unger C, Mross K. Treatment of anthracycline extravasation with dexrazoxane—clinical experience. Onkologie. 2006;29(7):314–8.PubMedCrossRef Frost A, Gmehling D, Azemar M, Unger C, Mross K. Treatment of anthracycline extravasation with dexrazoxane—clinical experience. Onkologie. 2006;29(7):314–8.PubMedCrossRef
23.
Zurück zum Zitat Mouridsen HT, Langer SW, Buter J, Eidtmann H, Rosti G, de Wit M, et al. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol. 2007;18(3):546–50.PubMedCrossRef Mouridsen HT, Langer SW, Buter J, Eidtmann H, Rosti G, de Wit M, et al. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol. 2007;18(3):546–50.PubMedCrossRef
25.
Zurück zum Zitat Tyson AM, Gay WE. Successful experience utilizing dexrazoxane treatment for an anthracycline extravasation. Ann Pharmacother. 2010;44(5):922–5.PubMedCrossRef Tyson AM, Gay WE. Successful experience utilizing dexrazoxane treatment for an anthracycline extravasation. Ann Pharmacother. 2010;44(5):922–5.PubMedCrossRef
31.
Zurück zum Zitat Langer SW, Thougaard AV, Sehested M, Jensen PB. Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane. Cancer Chemother Pharmacol. 2012;69(2):573–6. doi:10.1007/s00280-011-1794-6.PubMedCrossRef Langer SW, Thougaard AV, Sehested M, Jensen PB. Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane. Cancer Chemother Pharmacol. 2012;69(2):573–6. doi:10.​1007/​s00280-011-1794-6.PubMedCrossRef
36.
Zurück zum Zitat Anonymous. Dexrazoxane: new indication. Anthracycline extravasation: continue using dimethyl sulfoxide. Prescrire Int 2009;18(99):6–8. Anonymous. Dexrazoxane: new indication. Anthracycline extravasation: continue using dimethyl sulfoxide. Prescrire Int 2009;18(99):6–8.
37.
Zurück zum Zitat Wengstrom Y, Margulies A, European Oncology Nursing Society Task F. European Oncology Nursing Society extravasation guidelines. Eur J Oncol Nurs. 2008;12(4):357–61.PubMedCrossRef Wengstrom Y, Margulies A, European Oncology Nursing Society Task F. European Oncology Nursing Society extravasation guidelines. Eur J Oncol Nurs. 2008;12(4):357–61.PubMedCrossRef
38.
Zurück zum Zitat Pérez Fidalgo JA, García Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F et al. Management of chemotherapy extravasation: ESMO–EONS Clinical Practice Guidelines. Ann Oncol. 2012;23(suppl 7):vii167–vii73. doi:10.1093/annonc/mds294. Pérez Fidalgo JA, García Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F et al. Management of chemotherapy extravasation: ESMO–EONS Clinical Practice Guidelines. Ann Oncol. 2012;23(suppl 7):vii167–vii73. doi:10.​1093/​annonc/​mds294.
39.
Zurück zum Zitat Conde-Estevez D, Mateu-de Antonio J. Comment on: management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines. Ann Oncol. 2013;24(4):1128–9; author reply 9–30. doi:10.1093/annonc/mdt021 mdt021. Conde-Estevez D, Mateu-de Antonio J. Comment on: management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines. Ann Oncol. 2013;24(4):1128–9; author reply 9–30. doi:10.​1093/​annonc/​mdt021 mdt021.
Metadaten
Titel
Treatment of anthracycline extravasations using dexrazoxane
verfasst von
D. Conde-Estévez
J. Mateu-de Antonio
Publikationsdatum
01.01.2014
Verlag
Springer Milan
Erschienen in
Clinical and Translational Oncology / Ausgabe 1/2014
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1100-7

Weitere Artikel der Ausgabe 1/2014

Clinical and Translational Oncology 1/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.